Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Ensuring completeness and timeliness of cancer treatment guidelines

Timely and comprehensive updating of treatment guidelines remains a challenge and necessity in medical oncology. Herein we discuss our assessment of how trial results with four off-patent drugs have been considered for integration into major guidelines in the absence of a commercial sponsor, in which we found reasons for concern.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Elliott, J. et al. Decision makers need constantly updated evidence synthesis. Nature 600, 383–385 (2021).

    CAS  Article  Google Scholar 

  2. Ismaila, N., Salako, O., Mutiu, J. & Adebayo, O. Oncology guidelines usage in a low- and middle-income country. J. Glob. Oncol. 4, 1–6 (2018).

    PubMed  Google Scholar 

  3. Edwards, P. et al. Identification of randomized controlled trials in systematic reviews: accuracy and reliability of screening records. Stat. Med. 21, 1635–1640 (2002).

    Article  Google Scholar 

  4. Haddaway, N. R. et al. Eight problems with literature reviews and how to fix them. Nat. Ecol. Evol. 4, 1582–1589 (2020).

    Article  Google Scholar 

  5. Harris, M. et al. Explicit bias toward high-income-country research: a randomized, blinded, crossover experiment of English clinicians. Health Aff. 36, 1997–2004 (2017).

    Article  Google Scholar 

  6. Rauh, S. et al. Old drug, new clinical use, no man’s land for the indication: an awareness call from European experts. ESMO Open 5, e000615 (2020).

    Article  Google Scholar 

  7. Burchert, A. et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication Mutation (SORMAIN). J. Clin. Oncol. 38, 2993–3002 (2020).

    Article  Google Scholar 

  8. Xuan, L. et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 21, 1201–1212 (2020).

    CAS  Article  Google Scholar 

  9. Kluetz, P. G. et al. FDA Oncology Center of Excellence project renewal: engaging the oncology community to update product labeling for older oncology drugs. Clin. Cancer Res. 27, 916–921 (2021).

    CAS  Article  Google Scholar 

  10. Asker-Hagelberg, C. et al. Repurposing of medicines in the EU: launch of a pilot framework. Front. Med. 8, 817663 (2022).

    Article  Google Scholar 

Download references


The authors thank P. Pantziarka (Anticancer Fund) for discussions and assistance in preparing this article.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Gauthier Bouche.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

ASCO Guidelines Evidence Submission Form:

ASCO Guidelines Methodology Manual :

ESMO eUpdate standard operating procedures:

NCCN Submission Request History:

Transparency of the NCCN Guidelines Development Process:

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bouche, G., Meheus, L. Ensuring completeness and timeliness of cancer treatment guidelines. Nat Rev Clin Oncol (2022).

Download citation

  • Published:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing